At the time of the MBI of Laboratoires Filorga in 2006 with Didier Tabary and the EdRIP fund, the company was only making €5 million in revenue, spread across a large number of product families, including the production of mesotherapy products and the distribution of wrinkle fillers. The launch of its own-brand filler was imminent, but the product (sourced from a German laboratory) turned out not to be stable.
With the agreement of his shareholders, Didier Tabary then repositioned Filorga's business to focus on anti-aging cosmetics for the general public, based on mesotherapeutic active ingredients and hyaluronic acid. The resources devoted to creating a specific range, regularly updated with new products, to communication and especially to distribution, in order to penetrate specialist retail networks, bore fruit, with Filorga embarking on an uninterrupted period of strong growth, which continued with a new financial partner after the departure of EdRIP and Initiative & Finance.
Evolution of turnover
Type of investment
Changes in the number of employees
Sector of activity